<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02464878</url>
  </required_header>
  <id_info>
    <org_study_id>Islet after Kidney - AAT</org_study_id>
    <nct_id>NCT02464878</nct_id>
  </id_info>
  <brief_title>Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients meeting the study entry criteria will receive 1-3 infusion(s) of in vitro cultured
      islets. Patients will receive three times a week AAT infusions in the peri-transplant period
      for three weeks.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The proportion of GLASSIA versus control CIT06 subjects achieving insulin independence after first infusion of single donor islets.</measure>
    <time_frame>Day 75</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimated engrafted islet mass by FSIGT at post islet infusion comparing Glassia treated versus control subjects.</measure>
    <time_frame>Day 75</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The proportion of GLASSIA treated versus control CIT06 subjects who are insulin independent after 1 or more islet infusions</measure>
    <time_frame>1 year after the first islet infusion, 1 year after the last islet infusion, 2 years after the first islet infusion, 2 years after the last islet infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline insulin requirement comparing GLASSIA treated versus control CIT06 subjects</measure>
    <time_frame>Day 75, 1 year and 2 years following the first and last islet transplant(s)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The relative functional engrafted islet mass comparing GLASSIA treated versus control CIT06 subjects using FSIGT testing</measure>
    <time_frame>Day 75 after the first islet transplant , 1 year after the first islet transplant , 2 years after the first islet transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of markers of early islet loss as assessed by the rapid release of TAT, C3 and c-peptide, and insulin specific DNA with FSIGT and clinical markers of islet function</measure>
    <time_frame>Month 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of GLASSIA treated versus CIT06 control subjects with both an HbA1c ≤ 6.5% AND an absence of severe hypoglycemic events</measure>
    <time_frame>From Day 28 to Day 365 after the first islet transplant, From Day 28 to Day 730 after the first islet transplant.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of GLASSIA treated versus control subjects with both an HbA1c &lt; 7.0% AND free of severe hypoglycemic events</measure>
    <time_frame>From Day 28 to Day 365 after the first islet transplant, From Day 28 to Day 730 after the first islet transplant.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of GLASSIA treated versus control CIT06 subjects A reduction in HbA1c of 1 point AND an absence of severe hypoglycemia</measure>
    <time_frame>From Day 28 to Day 365 after the first islet transplant, From Day 28 to Day 730 after the first islet transplant.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ber of severe hypoglycemic events comparing GLASSIA treated versus control CIT06 subjects</measure>
    <time_frame>1 year and 2 years following the first and last islet transplant(s)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c comparing GLASSIA treated versus control CIT06 subjects</measure>
    <time_frame>1 year and 2 years following the first and last islet transplant(s)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The change in Clarke score from baseline in GLASSIA treated versus control CIT06 subjects</measure>
    <time_frame>1 year and 2 years after the first islet transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>β-score comparing GLASSIA treated versus control CIT06 subjects</measure>
    <time_frame>1 year and 2 years following the first and last islet transplant(s)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose variability and hypoglycemia duration derived from the CGMS comparing GLASSIA treated versus control CIT06 subjects</measure>
    <time_frame>1 year and 2 years following the first and last islet transplant(s)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basal (fasting) and 90-min glucose and c-peptide derived from the mixed-meal tolerance test (MMTT) comparing GLASSIA treated versus control CIT06 subjects</measure>
    <time_frame>1 year and 2 years following the first and last islet transplant(s)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MAGE comparing GLASSIA treated versus control CIT06 subjects</measure>
    <time_frame>1 year and 2 years following the first and last islet transplant(s)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic lability index (LI) comparing GLASSIA treated versus CIT06 control subjects</measure>
    <time_frame>1 year and 2 years following the first and last islet transplant(s)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ryan hypoglycemia severity (HYPO) Score comparing GLASSIA treated versus control CIT06 Subjects</measure>
    <time_frame>1 year and 2 years following the first and last islet transplant(s)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-peptide: (glucose· creatinine) ratio (CPGCR) comparing GLASSIA treated versus control CIT06 subjects</measure>
    <time_frame>1 year and 2 years following the first and last islet transplant(s)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of favorable outcome at each center preparing islets (rate of subjects with HbA1c &lt; 6.5% and absence of severe hypoglycemic events, or reduction in HbA1c of 1 point and absence of severe hypoglycemia</measure>
    <time_frame>Day 28 to Day 730</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects receiving a second islet transplant comparing GLASSIA treated versus control CIT06 subjects</measure>
    <time_frame>1 year and 2 years following the first and last islet transplant(s)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The proportion of subjects receiving a third islet transplant comparing GLASSIA treated versus control CIT06 subjects</measure>
    <time_frame>1 year and 2 years following the first and last islet transplant(s)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular events [death, cerebrovascular accident (CVA), myocardial infarction (MI)] and changes in atherogenic profile for GLASSIA treated versus control subjects</measure>
    <time_frame>1 year and 2 years following the first and last islet transplant(s)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal impact measures including renal allograft survival and function measured by serum creatinine (SCr) and urinary albumin creatinine ratio comparing GLASSIA treated versus control subjects</measure>
    <time_frame>1 year and 2 years following the first and last islet transplant(s)</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Assessment of the effect of AAT on serum cytokines released in the early post transplant period (1 month) comparing GLASSIA versus control subjects from CIT06</measure>
    <time_frame>1 month</time_frame>
    <description>Exploratory Mechanistic Endpoints</description>
  </other_outcome>
  <other_outcome>
    <measure>Assessment of the effect of AAT on the inflammatory gene transcriptional profile of PBL</measure>
    <time_frame>day 14 and 75</time_frame>
    <description>Exploratory Mechanistic Endpoints</description>
  </other_outcome>
  <other_outcome>
    <measure>Correlation of reaching target AAT levels with metabolic outcomes</measure>
    <time_frame>1 Year</time_frame>
    <description>Exploratory Mechanistic Endpoints</description>
  </other_outcome>
  <other_outcome>
    <measure>Histological survival of subcutaneous islets in subcutaneous auxiliary graft and correlation with overall graft survival</measure>
    <time_frame>1 Year</time_frame>
    <description>Exploratory Mechanistic Endpoints</description>
  </other_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Kidney Transplant</condition>
  <condition>Type 1 Diabetes</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alpha 1-Antitrypsin</intervention_name>
    <description>Patients will receive three times a week AAT infusions in the peri-transplant period for three weeks.</description>
    <other_name>Glassia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Islet Transplantation</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin</intervention_name>
    <description>Patients will receive a total of 5 doses between Day -2 and Day +2</description>
    <other_name>Antithymocyte Globulin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Basiliximab</intervention_name>
    <description>Basiliximab will be used for subsequent transplants.</description>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etanercept</intervention_name>
    <description>Etanercept will be given on the day of transplant and on Days 3, 7, and 10 post-transplant.</description>
    <other_name>Enbrel</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female subjects age 18 to 70 years.

          -  Subjects who are able to provide written informed consent and to comply with the
             procedures of the study protocol.

          -  Subjects must have one of the following payment mechanisms in place:

               1. Medicare,

               2. A third-party insurer who agrees, via pre-authorization, to pay for participation
                  in the study, or

               3. Another mechanism of payment (self-pay, hospital, university, donations, etc.)
                  for participation in the study.

          -  Clinical history compatible with T1D with disease onset &lt; 40 years of age and
             insulin-dependence for ≥ 5 years at the time of enrollment.

          -  Absent stimulated c-peptide (&lt; 0.3 ng/mL) in response to a MMTT [Boost® 6 mL/kg body
             weight (BW) to a maximum of 360 mL; another product with equivalent caloric and
             nutrient content may be substituted for Boost®] measured at 60 and 90 min after start
             of consumption.

          -  Subjects who are ≥ 3 months post-renal transplant who are taking appropriate
             calcineurin inhibitor (CNI) based maintenance immunosuppression ([tacrolimus alone or
             in conjunction with sirolimus, mycophenolate mofetil, myfortic, or azathioprine; or
             cyclosporine in conjunction with sirolimus, mycophenolate mofetil, or myfortic] ±
             Prednisone ≤ 10 mg/day).

          -  Stable renal function as defined by a creatinine of no more than one third greater
             than the average creatinine determination performed in the 3 previous months prior to
             islet transplantation, until rejection, obstruction or infection is ruled out.

          -  Subjects who meet one of the options in the following criterion are eligible for
             transplantation:

               -  Reduced awareness of hypoglycemia manifested by a Clarke score of 4 or more
                  measured upon study enrollment and at least one episode of severe hypoglycemia in
                  the 12 months prior to study enrollment.

               -  A subject must have a reduced awareness of hypoglycemia manifested by a Clarke
                  score of 4 or more and at least 1 episode of severe hypoglycemia;

               -  Any subject not meeting the hypoglycemia option must have an HbA1c &gt; 7.5%.

        Exclusion Criteria:

          -  Weight more than 100 kg or body mass index (BMI) &gt; 33 kg/m2.

          -  Insulin requirement of &gt;1.0 U/kg/day or, &gt; 60 U/day total, or &lt;15 U/day.

          -  Other (non-kidney) organ transplants except prior failed pancreatic graft where graft
             failure is attributed to thrombosis within the first 4 weeks or to other technical
             reasons that require graft pancreatectomy; with the graft pancreatectomy occurring
             more than 6 months ago.

          -  Untreated or unstable proliferative diabetic retinopathy.

          -  Blood Pressure: SBP &gt; 160 mmHg or DBP &gt;100 mmHg despite treatment with
             antihypertensive agents.

          -  Calculated GFR of ≤ 40 mL/min/1.73 m2 using the subject's measured serum creatinine
             and the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation1. Strict
             vegetarians (vegans) will be excluded only if their estimated GFR is ≤ 35 mL/min/1.73
             m2.

             7. Proteinuria (albumin/creatinine ratio or ACr &gt; 300mg/g) of new onset since kidney
             transplantation.

          -  Calculated panel-reactive anti-HLA antibodies &gt; 50%. Subjects with calculated panel
             reactive anti-HLA antibodies ≤ 50% will be excluded if any of the following are
             detected:

               -  Positive cross-match,

               -  Islet donor-directed anti-HLA antibodies detected by Luminex Single
                  Antigen/specificity bead assay including weakly reactive antibodies that would
                  not be detected by a flow cross-match, or

               -  Antibodies to the renal donor (i.e. presumed de novo).

          -  For female subjects: Positive pregnancy test, presently breast-feeding, or
             unwillingness to use effective contraceptive measures for the duration of the study
             and 4 months after discontinuation. For male subjects: intent to procreate during the
             duration of the study or within 4 months after discontinuation or unwillingness to use
             effective measures of contraception. Oral contraceptives, Norplant®, Depo-Provera®,
             and barrier devices with spermicide are acceptable contraceptive methods; condoms used
             alone are not acceptable.

          -  Presence or history of active infection including hepatitis B, hepatitis C, HIV, or
             tuberculosis (TB). Subjects with laboratory evidence of active infection are excluded
             even in the absence of clinical evidence of active infection.

          -  Negative screen for Epstein-Barr virus (EBV) by IgG determination at time of screening
             or previous kidney transplant.

          -  Invasive aspergillus, histoplasmosis, and coccidoidomycosis infection within the last
             year.

          -  Any history of malignancy except for completely resected squamous or basal cell
             carcinoma of the skin.

          -  Known active alcohol or substance abuse.

          -  Any coagulopathy or medical condition requiring long-term anticoagulant therapy (e.g.
             warfarin) after islet transplantation (low-dose aspirin treatment [325 mg PO] is
             allowed) or subjects with international normalized ratio (INR) &gt; 1.5. The use of
             Plavix is allowed only in conjunction with mini- laparotomy procedure at the time of
             islet transplant.

          -  Severe co-existing cardiac disease, characterized by any one of these conditions:

               -  Recent MI (within past 6 months);

               -  Evidence of ischemia on functional cardiac exam within the last year;

               -  Left ventricular ejection fraction &lt; 30%; or

               -  Valvular disease requiring replacement with prosthetic valve.

          -  Persistent serum glutamic-oxaloacetic transaminase (SGOT [AST]), serum glutamate
             pyruvate transaminase (SGPT [ALT],) alkaline phosphatase or total bilirubin, with
             values &gt; 1.5 times normal upper limits will exclude a subject.

          -  Active infections (except mild skin and nail fungal infections).

          -  Acute or chronic pancreatitis.

          -  Active peptic ulcer disease, symptomatic gallstones, or portal hypertension.

          -  Use of any investigational agents within 4 weeks of enrollment.

          -  Administration of live attenuated vaccine(s) within 2 months of enrollment.

          -  Any medical condition that, in the opinion of the investigator, will interfere with
             the safe participation in the trial. (Cancer screenings should be performed per
             current American Cancer Society guidelines).

          -  Positive screen for BK virus by polymerase chain reaction (PCR) performed at time of
             screening.

          -  A kidney transplant patient with type 1 diabetes who has an HbA1c &lt; 7.5 and no history
             of severe hypoglycemia.

          -  Selective or severe IgA deficiency (levels &lt; 5-7 mg/dL)

          -  AAT deficiency (defined as &lt; 1.0ng/mg AAT)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jim Markmann, M.D. Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>James F Markmann, M.D. Ph.D.</last_name>
    <phone>617-643-4533</phone>
    <email>jmarkmann@mgh.harvard.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kerry Crisalli, RN BSN CRCC</last_name>
    <phone>617-643-4087</phone>
    <email>kcrisalli@mgh.harvard.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>James F Markmann, MD, PhD</last_name>
      <phone>617-643-4533</phone>
      <email>jmarkmann@mgh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kerry Crisalli, RN, BSN</last_name>
      <phone>617-643-4087</phone>
      <email>kcrisalli@mgh.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>James F Markmann, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 3, 2015</study_first_submitted>
  <study_first_submitted_qc>June 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 8, 2015</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>James F. Markmann, MD, PhD</investigator_full_name>
    <investigator_title>Chief, Division of Transplant Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etanercept</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Basiliximab</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Alpha 1-Antitrypsin</mesh_term>
    <mesh_term>Protein C Inhibitor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

